Condition: Tuberculosis, Latent · Sponsor: Johns Hopkins University
A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks of follow-up among people living with HIV (PLHIV) and high-risk Close Contacts (CC) of adults with Drug Susceptible (DS) or Rifampin Resistant (RR) TB.
This description comes directly from the study's public registry record.
Bonnie S. King, MHS · 4106249189 · bking6@jh.edu
Kate Boehner, RN, MSN · 2012592222 · kate.b@jhu.edu
Always discuss trial participation with your own doctor first.
| HNSEB (Hospital Nacional Sergio E. Bernales) | Lima, Peru | Not Yet Recruiting |
| SES Policlinico | Lima, Peru | Not Yet Recruiting |
| Kilimanjaro Clinical Research Institute | Moshi, Tanzania | Recruiting |
| Joint Clinical Research Centre | Kampala, Uganda | Recruiting |
| Makerere Lung Institute | Kampala, Uganda | Not Yet Recruiting |
| MU-JHU Care Ltd. | Kampala, Uganda | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568484